High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.

Annals of hepatology - 1 Jan 2000

Crespo Javier, Diago Moisés, Cabezas Joaquín, Berenguer Marina, Broquetas Teresa, Serra Miguel Ángel, Morillas Rosa, García-Samaniego Javier, Calleja José Luis, Sánchez Juan José, Lens Sabela, Soto-Fernández Susana, Sacristán Begoña, Fernández Inmaculada, López-Núñez Carmen, Buti María, Romero-Gómez Manuel, Sáez-Royuela Federico, Fernández Conrado, Jorquera Francisco, Sánchez-Antolín Gloria, Pascasio Juan Manuel, Cuadrado Antonio, Hernández-Guerra Manuel

Abstract excerpt

BACKGROUND AND RATIONAL: Telaprevir-based therapy (TBT) has been extensively evaluated in clinical trials. So we designed a study to compare the efficacy and safety of TBT between patients with moderate fibrosis and those suffering from advanced fibrosis in clinical practice. A multicenter observational and ambispective study was conducted. It included 582 patients with chronic hepatitis C genotype 1, 214 with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferons

Share to Interleukins

Share to Liver Cirrhosis

Share to Oligopeptides

Share to Spain

Share to Viral Load

Source

Open in PubMed

Identifiers

PMID: 26019034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.PMID 26019034Read ↗

Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.Semantic proximity Read ↗

Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.Semantic proximity Read ↗

A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis.Semantic proximity Read ↗

[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].Semantic proximity Read ↗

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.Semantic proximity Read ↗

Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil.Semantic proximity Read ↗

[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].Semantic proximity Read ↗

Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience.Semantic proximity Read ↗

Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.Semantic proximity Read ↗

Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort.Semantic proximity Read ↗

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.